Valuation: MindWalk Holdings Corp.

Market Cap 66.47M 46.64M 42.27M 39.09M 35.27M 4.4B 68.81M 470M 186M 2.35B 175M 171M 7.46B P/E 2027 *
-3.38x
P/E 2028 * -3.91x
Enterprise Value 66.47M 46.64M 42.27M 39.09M 35.27M 4.4B 68.81M 470M 186M 2.35B 175M 171M 7.46B EV / Sales 2027 *
3.79x
EV / Sales 2028 * 3.08x
Free-Float
90.75%
Yield 2027 *
-
Yield 2028 * -
11-04 MindWalk Holdings Corp. Announces Agreement With Teva Pharmaceuticals Australia Pty Ltd To Support Defined Antibody-Discovery Workflows CI
10-23 Mindwalk Holdings Corp. Announces Departure of Thomas Lynch as Chief Business Officer, Effective October 16, 2026 CI
10-21 MindWalk Holdings Corp., NVIDIA Corporation, Absci Corporation And AbCellera Biologics Inc. Provide Product Updates For LensAI, BioNeMo Agent Toolkit, ABS-201 And ABCL635 CI
10-14 Mindwalk Holdings Corp. Announces Management Changes CI
10-06 MindWalk Holdings Corp. Outlines ReefIQ As Biological Context Layer For Life Sciences Powered By HYFT Technology CI
10-01 MindWalk Holdings Corp. Announces Appointment of Kim Remizowski as Independent Director, Audit Committee Member and Compensation, Nomination and Governance Committee Member, Effective September 29, 2026 CI
09-21 Mindwalk Holdings Corp. Brings Openfold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine CI
09-15 MindWalk Holdings Corp., Q1 2027 Earnings Call, Sep 14, 2026
09-15 MindWalk Fiscal Q1 Loss Widens, Revenue Rises MT
09-14 MindWalk Holdings Corp. Reports Earnings Results for the First Quarter Ended July 31, 2026 CI
09-14 Mindwalk Holdings Corp. Enters into Binding Commitment for USD 30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion CI
07-23 Tranche Update on MindWalk Holdings Corp.'s Equity Buyback Plan announced on October 9, 2025. CI
07-23 MindWalk Holdings Corp., Q4 2026 Earnings Call, Jul 22, 2026
1 day-1.00%
1 week-6.60%
Current month-12.39%
1 month-27.74%
3 months-29.79%
6 months-21.43%
Current year-45.60%
1 week 0.91
Extreme 0.9111
1.12
1 month 0.91
Extreme 0.9111
1.42
Current year 0.91
Extreme 0.9111
2.99
1 year 0.91
Extreme 0.9111
2.99
3 years 0.27
Extreme 0.27
3.25
5 years 0.27
Extreme 0.27
6.88
10 years 0.27
Extreme 0.27
33.34
Manager TitleAgeSince
Chief Executive Officer - 21/02/2018
Director of Finance/CFO 62 20/10/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 24/05/2018
Chairman - -
Director/Board Member 56 07/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
8/19/26 A Option

Executive/Senior Manager

-12,500 0.0271%
8/19/26 A Option

Responsable ventes & marketing

7,443 0.0161%
8/19/26 A Option

Executive/Senior Manager

8,473 0.0184%
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-6.60%-41.07%-32.65% 46.64M
+1.26%+6.61%+40.79%+136.32% 1,286B
+0.79%+3.45%+45.84%+93.52% 688B
+0.20%+1.28%+26.97%+113.70% 521B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+44.62% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+72.46% 252B
+0.08%+0.71%+34.44%+124.95% 208B
Average +0.14%+1.21%+27.74%+71.76% 429B
Weighted average by Cap. +0.54%+3.26%+37.70%+96.50%

Financials

2027 *2028 *
Net sales 17.56M 12.32M 11.16M 10.33M 9.32M 1.16B 18.18M 124M 49.19M 621M 46.23M 45.25M 1.97B 21.59M 15.15M 13.73M 12.7M 11.45M 1.43B 22.35M 153M 60.47M 763M 56.84M 55.63M 2.42B
Net income -19.36M -13.58M -12.31M -11.39M -10.27M -1.28B -20.04M -137M -54.24M -684M -50.98M -49.9M -2.17B -17.23M -12.09M -10.96M -10.13M -9.14M -1.14B -17.84M -122M -48.28M -609M -45.38M -44.41M -1.93B
Net Debt - -
Projected Income Statement - Annual - MindWalk Holdings Corp.
Logo MindWalk Holdings Corp.
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
Employees
76
Date Price Change Volume
13/11/26 $0.9900 -1.00% 350,324
12/11/26 $1.000 -2.91% 223,209
11/11/26 $1.030 0.00% 80,301
10/11/26 $1.030 -4.63% 144,271
09/11/26 $1.080 +1.89% 202,567
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - MindWalk Holdings Corp.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9900USD
Average target price
4.333USD
Spread / Average Target
+337.71%
  1. Stock Market
  2. Stocks
  3. HYFT Stock